In the BioHarmony Drug Report Database

"Preview" Icon

Pimozide

Orap (pimozide) is a small molecule pharmaceutical. Pimozide was first approved as Orap on 1984-07-31. It is used to treat huntington disease, psychotic disorders, schizophrenia spectrum and other psychotic disorders, and tourette syndrome in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A and D(2) dopamine receptor. In addition, it is known to target G protein-activated inward rectifier potassium channel 2, histamine H1 receptor, D(3) dopamine receptor, potassium voltage-gated channel subfamily A member 10, 5-hydroxytryptamine receptor 1A, voltage-dependent T-type calcium channel subunit alpha-1I, voltage-dependent T-type calcium channel subunit alpha-1G, 5-hydroxytryptamine receptor 7, voltage-dependent T-type calcium channel subunit alpha-1H, and 5-hydroxytryptamine receptor 6.

 

Trade Name

 

Orap
 

Common Name

 

pimozide
 

ChEMBL ID

 

CHEMBL1423
 

Indication

 

huntington disease, psychotic disorders, schizophrenia spectrum and other psychotic disorders, tourette syndrome
 

Drug Class

 

Typical antipsychotic

Image (chem structure or protein)

Pimozide structure rendering